Evamist.com HCP– Evamist® transdermal profile (estradiol transdermal spray)

Evamist^® delivers efficacy with a low dose

As recommended by the FDA, estrogen should be used in the lowest dose for the shortest duration needed.¹ Evamist delivers a low dose of 17ß-estradiol sprayed on a small area of the forearm. Evamist has proven efficacy with low serum estradiol levels compared with other transdermal estrogen therapies.^2,3

The estrogen in Evamist is chemically synthesized from a plant source.³
This does not mean Evamist is safer or more effective than other
hormone therapies.

Not all transdermal products are created equal

Transdermal delivery of estrogen was an advancement in the delivery of hormone therapy. However, not all transdermal products are created equal, and other transdermal products have disadvantages. Take a look at patches for instance…they can^4-6:

Fall off
Have irregular change schedules (3, 4, or 7 days)
Lead to localized irritation of the skin
Get dirty
Leave sticky adhesive residue
Be felt on the skin and visible to others

And gels and lotion may^7-10:

Need to be touched with the hands
Cover entire arm or leg
Take a longer time to dry

Evamist spray is more discreet than even the smallest patch, with no-touch application

Simple spray dries in a median of 67 seconds^†3
No need to worry about patch peeling or adhesive residue³
Fits easily into her daily routine
Flexible titration with three dosing options in one applicator²

As reported in an experience study of 247 women using Evamist, 90 of whom had no prior estrogen use.³

†

Patients should let spray dry for at least 2 minutes before dressing and at least 30 minutes before washing.²

» References

Important Safety Information

Indication
Evamist^® is indicated for the treatment of moderate-to-severe vasomotor symptoms due to menopause.

WARNING—ENDOMETRIAL CANCER, CARDIOVASCULAR, AND OTHER RISKS

ENDOMETRIAL CANCER Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding.

CARDIOVASCULAR AND OTHER RISKS Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia. The Women’s Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 6.8 years and 7.1 years, respectively, of treatment with daily oral conjugated estrogens (CE 0.625 mg), relative to placebo. The estrogen plus progestin WHI substudy reported increased risk of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and DVT in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral CE 0.625 mg combined with medroxyprogesterone acetate (MPA 2.5 mg), relative to placebo. The Women’s Health Initiative Memory Study (WHIMS), a substudy of the WHI, reported increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE 0.625 mg alone and during 4 years of treatment with daily CE 0.625 mg combined with MPA 2.5 mg, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women. In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA and other combinations and dosage forms of estrogens and progestins. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

Evamist should not be used in women with undiagnosed abnormal genital bleeding; known, suspected, or history of breast cancer; known or suspected estrogen-dependent neoplasia; active deep vein thrombosis, pulmonary embolism, or history of these conditions; active or recent arterial thromboembolic disease; liver dysfunction or disease; or known or suspected pregnancy.

In a clinical trial with Evamist, the most common side effects were headache, breast tenderness, nasopharyngitis, nipple pain, back pain, nausea, and arthralgia.

Please see full prescribing information for Evamist, including boxed warnings.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.